Arch Therapeutics, Inc. (ARTHQ)

Market Cap	444.00
Revenue (ttm)	148.16K
Net Income (ttm)	-12.99M
Shares Out	4.44M
EPS (ttm)	-2.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	792
Average Volume	3,334
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.1573 - 1.5670
Beta	4.03
RSI	18.91
Earnings Date	May 9, 2025

About Arch Therapeutics

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company’s flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARTHQ

Financial Performance

In 2023, Arch Therapeutics's revenue was $75,724, an increase of 383.80% compared to the previous year's $15,652. Losses were -$6.98 million, 32.4% more than in 2022.